Localization of plasminogen activator inhibitor type 1 and 2 in preimplantation mouse development in vitro

Abstract

Plasminogen activator inhibitor type 1 (PAI-1) and type 2 (PAI-2) are the major endogenous inhibitors of fibrinolysis, or thrombolysis, as it is effective in blocking the conversion of plasminogen to plasmin. In mammalian embryos, both PAI-1 and PAI-2 proteins are expressed in the trophoblasts during and after implantation, suggesting their critical roles in implantation and placentation during pregnancy. However, it remains unclear how both proteins localize in the early stage embryos before implantation. In this study, 2 cell stage embryos were flushed from the oviducts and cultured to specified stages in medium at 37 ̊C in a 5% CO₂ incubator. Embryos were fixed and double immunostained with anti-PAI-1 and anti- PAI-2 antibody. We determined the critical expression and localization patterns of PAI-1 and PAI-2 proteins in murine preimplantation embryos at 2 cell, 8 cell, morula and blastocyst stages by using confocal laser scanning microscope. We found that PAI-1 and PAI-2 constantly express in the embryos during preimplantation development, and these proteins localize in both the cytoplasm and the nucleus of each blastomere regardless of their developmental stage. Our results suggest that PAI-1 and PAI-2 proteins may play roles in early embryonic development before implantation.

Keywords

• Embryo development,PAI-1,PAI-2,preimplantation

References

1. 1. Aflalo ED, Sod-Moriah UA, Potashnik G, et al (2005): Expression of plasminogen activators in preimplantation rat embryos developed in vivo and in vitro. Reprod Biol Endocrinol, 3, 7.
2. 2. Astedt B, Lindoff C, Lecander I (1998): Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy. Semin Thromb Hemost, 24, 431-435.
3. 3. Balsara RD, Ploplis VA (2008): Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thromb Haemost, 100, 1029-1036.
4. 4. Brenner B (2004): Haemostatic changes in pregnancy. Thromb Res, 114, 409-414.
5. 5. Canipari R, Strickland S (1985): Plasminogen activator in the rat ovary. Production and gonadotropin regulation of the enzyme in granulosa and thecal cells. J Biol Chem, 260, 5121-5125.
6. 6. Carmeliet P, Kieckens L, Schoonjans L, et al (1993): Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest, 92, 2746-2755.
7. 7. Collen D (1980): On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost, 43, 77-89.
8. 8. Dougherty KM, Pearson JM, Yang AY, et al (1999): The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. Proc Natl Acad Sci USA, 96, 686-691.

9. 9. Fang H, Placencio VR, DeClerck YA (2012): Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J Natl Cancer Inst, 104, 1470-1484.
10. 10. Feinberg RF, Kao LC, Haimowitz JE, et al (1989): Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker of invading trophoblasts. Lab Investig J Tech Methods Pathol, 61, 20-26.
11. 11. Feng Q, Liu Y, Liu K, et al (2000): Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation. Placenta, 21, 184-193.
12. 12. Giacoia EG, Miyake M, Lawton A, et al (2014): PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation. Mol Cancer Res, 12, 322-334.
13. 13. Giacoia EG, Miyake M, Goodison S, et al (2013): Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther, 12, 2697-2708.
14. 14. Hellgren M (2003): Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost, 29, 125-130.
15. 15. Hofmann GE, Glatstein I, Schatz F, Heller D, et al (1994): Immunohistochemical localization of urokinase-type plasminogen activator and the plasminogen activator inhibitors 1 and 2 in early human implantation sites. Am J Obstet Gynecol, 170, 671-676.
16. 16. Huarte J, Belin D, Vassalli JD (1985): Plasminogen activator in mouse and rat oocytes: induction during meiotic maturation. Cell, 43, 551-558.
17. 17. Huarte J, Vassalli, JD, Belin D, et al (1993): Involvement of the plasminogen activator/plasmin proteolytic cascade in fertilization. Dev Biol, 157, 539-46.
18. 18. Kaufmann P, Black S, Huppertz B (2003): Endovascular trophoblast invasion: Implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod, 69, 1-7.
22. 19. Lee CC, Huang TS (2005): Plasminogen activator inhibitor-1: the expression, biological functionsand effects on tumorigenesis and tumor cell adhesion and migration. J Cancer Mol, 1, 25-36. 20. Lijnen HR (2005): Pleiotropic functions of plasminogen activator inhibitor- 1. J Thromb Haemost, 3, 35-45. 21. Liu YX (2004): Plasminogen activator/plasminogen activator inhibitors in ovarian physiology. Front Biosci, 9, 3356-3373. 22. Markiewski MM, Nilsson B, Ekdahl KN, et al (2007): Complement and coagulation: strangers or partners in crime? Trends Immunol, 28, 184-192. 23. Mashiko S, Kitatani K, Toyoshima M, et al (2015): Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biol Ther, 16, 253-260. 24. Mehta BN, Nath N, Chimote N (2014): Periodicity in the levels of serum plasminogen activator inhibitor-1 is a robust prognostic factor for embryo implantation and clinical pregnancy in ongoing IVF cycles. J Hum Reprod Sci, 7, 198-205. 25. Mutluay D (2016): Distribution of primitive endoderm and epiblast lineage specific factors in late stage blastocysts. Slov Vet Res, 53, 211-217. 26. Mutluay D, Oner H (2017) The Abelson tyrosine kinase (c-Abl) localization in preimplantation mouse development. Rom J Morphol Embryol, 58, 1385-1391. 27. Pihusch M, Pihusch V, Holler E (2005): Plasminogen activator inhibitor-1: A review. J Lab Med, 29, 403-411. 28. Placencio VR, DeClerck YA (2015): Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. Cancer Res, 75, 2969-2974. 29. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Danø K (1991): The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res, 51, 4067-4071. 30. Saksela, O, Rifkin DB (1988): Cell-associated plasminogen activation: Regulation and physiological functions. Annu Rev Cell Biol, 4, 93-126. 31. Sappino AP, Huarte J, Belin D, et al (1989): Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos. J Cell Biol, 109, 2471-2479. 32. Soares MJ, Chakraborty D, Kubota K, et al (2014): Adaptive mechanisms controlling uterine spiral artery remodeling during the establishment of pregnancy. Int J Dev Biol, 58, 247-259. 33. Ye Y, Vattai A, Zhang X, et al (2017): Role of plasminogen activator inhibitor type 1 in pathologies of female reproductive diseases. Int J Mol Sci, 18, pii: E1651. 34. Zhang X, Rutledge J, Khamsi F, et al (1992): Release of tissue-type plasminogen activator by activated rat eggs and its possible role in the zona reaction. Mol Reprod Dev, 32, 28-32.